Early-Stage drug study halted: no safety data collected
NCT ID NCT07039929
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 36 times
Summary
This early-stage study aimed to check the safety and how the body handles a new drug called INCB000631 in 24 healthy adults aged 19 to 55. Participants would have taken multiple doses of the drug or a placebo. However, the study was terminated before completion, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion, Inc
Lincoln, Nebraska, 68502, United States
Conditions
Explore the condition pages connected to this study.